SYBX
Synlogic Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Market Cap: 17 Million
Primary Exchange: NASDAQ
Website: https://www.synlogictx.com/
Shares Outstanding: 9.19 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.5662113102133581
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1515 trading days
From: 2015-12-17 To: 2024-03-07
Lowest Point:
Microcaps dominate midday movers
via: SeekingAlpha at 2019-06-12 08:39:07:000
Gainers: Synlogic (NASDAQ: SYBX ) +28% . Immuron (NASDAQ: IMRN ) +26% . B Communications (NASDAQ: BCOM ) +23% . Arcadia Biosciences (NASDAQ: RKDA ) +17% . Vuzix Corporation (NASDAQ: VUZI ) +14% . MagnaChip Semiconductor Corporation (NYSE: MX ) +13% . Osmotica Pharmaceuticals (N… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-06-12 08:39:07:000
Gainers: Synlogic (NASDAQ: SYBX ) +28% . Immuron (NASDAQ: IMRN ) +26% . B Communications (NASDAQ: BCOM ) +23% . Arcadia Biosciences (NASDAQ: RKDA ) +17% . Vuzix Corporation (NASDAQ: VUZI ) +14% . MagnaChip Semiconductor Corporation (NYSE: MX ) +13% . Osmotica Pharmaceuticals (N… read more...
SYBX, MAT among premarket gainers
via: SeekingAlpha at 2019-06-12 05:16:31:000
Synlogic (NASDAQ: SYBX ) +26% as Ginkgo Bioworks to invest $80M . More news on: Synlogic, Inc., Bridgeline Digital, Inc., MagnaChip Semiconductor Corporation, , Stocks on the move Read more … read more...
SYBX, MAT among premarket gainers
via: SeekingAlpha at 2019-06-12 05:16:31:000
Synlogic (NASDAQ: SYBX ) +26% as Ginkgo Bioworks to invest $80M . More news on: Synlogic, Inc., Bridgeline Digital, Inc., MagnaChip Semiconductor Corporation, , Stocks on the move Read more … read more...
Ginkgo Bioworks to invest $80M in Synlogic at a premium
via: SeekingAlpha at 2019-06-12 02:49:08:000
Synlogic (NASDAQ: SYBX ) and Ginkgo Bioworks announce a platform collaboration to accelerate expansion and development of Synlogic's pipeline of Synthetic Bioticmedicines using Ginkgo's cell programming platform for building and testing microbial strains to accelerate progression of early pr… read more...
Ginkgo Bioworks to invest $80M in Synlogic at a premium
via: SeekingAlpha at 2019-06-12 02:49:08:000
Synlogic (NASDAQ: SYBX ) and Ginkgo Bioworks announce a platform collaboration to accelerate expansion and development of Synlogic's pipeline of Synthetic Bioticmedicines using Ginkgo's cell programming platform for building and testing microbial strains to accelerate progression of early pr… read more...
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic(TM) Medicines
via: Business Wire at 2019-06-12 02:30:00:000
Fuels development of Synlogics growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium Applies Ginkgos high-throughput synthetic biology platform services to human therapeutics –… read more...
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic(TM) Medicines
via: Business Wire at 2019-06-12 02:30:00:000
Fuels development of Synlogics growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium Applies Ginkgos high-throughput synthetic biology platform services to human therapeutics –… read more...
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|---|---|---|---|---|---|
2017-08-28 | 7.0 | 1.0 | 7.0 |